Haleon Corp (HLN) Market Cap to Earnings

Corporate emblem and logo of Haleon Group (HLN)

Haleon plc demonstrates high resilience to macroeconomic shocks due to stable demand for hygiene products. The company's forward P/E clearly illustrates the dynamics of market valuation relative to earnings, where 18.60 represents the current level of the metric. Growth is driven by the expansion of global mega-brands into new markets, while efficiency is maintained through the automation of packaging lines at its plants.

HLN: haleon.com P/E Multiple 04/28/2023 - 11/15/2026

Analytical breakdowns for Haleon plc

- share price and expert price forecast:
Summary company analysis:Haleon - HLN
Original product of Haleon Corp

Haleon plc (HLN) creates high business added value through its innovative approach to developing safe hygiene products. The P/E ratio reflects this efficiency by relating the current market share price to the net earnings per share. This metric determines the investment payback period and the extent of the premium paid for future growth. By analyzing the P/E volatility of Haleon plc (HLN), an investor can timely identify phases of asset overvaluation or undervaluation.

Key competitors

P/E Multiple Kenvue Corp|Price to Earnings Ratio VRNA (Verona Pharma Corp)|MENS (Jyong Bio) - Company Value to Net Income|Price to Earnings Ratio Ligand Pharmaceuticals Incorporated LGND|Amneal (AMRX) - Market Cap to Earnings|PRGO: Price to Earnings Ratio|Alvotech SA - Market Price to Net Income Ratio|LQDA: P/E Multiple|Galapagos Genomics - Company Value to Net Income|ANIP (ANI Pharmaceuticals Inc) - P/E Multiple|Market Cap to Earnings mannkindcorp.com MNKD|Price to Earnings Ratio Amphastar Pharmaceuticals, Inc. (AMPH)|PCRX (Pacira Pharmaceuticals) - Company Value to Net Income|P/E Multiple SPRY (ARS Pharmaceuticals Inc)|Market Price to Net Income Ratio TBPH (Theravance)|AQST - Price to Earnings Ratio|scPharmaceuticals (SCPH) - Price to Earnings Ratio|TECX: P/E Multiple|Price to Earnings Multiple TNXP|Price to Earnings Ratio China SXT Pharmaceuticals, Inc.|EPRX: Company Value to Net Income|P/E Multiple BHST|EXOZ - Market Cap to Earnings|P/E Multiple ORMP (oramed.com)|P/E Multiple enterabio.com ENTX|HYFT - Price to Earnings Ratio|Business Payback Period ABVC BioPharma, Inc ABVC|CPIX: P/E Multiple|Quantum BioPharma Ltd - Company Value to Net Income|Price to Earnings Ratio FGEN|Telomir Pharmaceuticals, Inc. - Market Cap to Net Income|P/E Multiple RANI|SNYR (Synergy CHC) - Company Value to Net Income|Price to Earnings Ratio Rallybio RLYB|Lexaria Bioscience (LEXX) - Market Cap to Earnings|PULM - Price to Earnings Ratio|Business Payback Period Pheton Holdings PTHL|APM (Aptorum) - Price to Earnings Ratio|Lyra Therapeutics, Inc. (LYRA) - P/E Multiple|IBO (impactbiomedinc.com) - P/E Multiple|TNFA (TNF Pharmaceuticals) - Market Price to Net Income Ratio|Price to Earnings Ratio cbdmd.com (YCBD)|Business Payback Period PainReform Ltd|P/E Multiple CYTO (Altamira Therapeutics Ltd.)|Lipella Pharmaceuticals (LIPO) - Market Cap to Earnings|OPTN - Price to Earnings Ratio|Pieris Pharmaceuticals - Market Price to Net Income Ratio|PROC (Procaps Group) - Price to Earnings Ratio|PTPI - Business Payback Period|Price to Earnings Ratio Qilian International Holding Group Limited|SLRN: Company Value to Net Income|Price to Earnings Ratio TFFP (TFF Pharma)